Caribou Biosciences Announces Strategic Alternatives Review, Discontinues Vispa-Cel And CB-011 CAR-T Programs, Cuts Workforce; Had $113.8M Cash At June 30
Share
Why It Matters
Caribou Biosciences stopped work on two medicine projects. The company is trying to find ways to survive with less money and fewer workers.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.